Nucleus Genomics, a New York-based next-generation consumer genetic testing and analysis company, raised $14m in funding.
The round was led by Alexis Ohanian’s Seven Seven Six, which joined a lineup of investors across technology, healthcare, and media, including Founders Fund, Adrian Aoun(CEO, Forward Health), Brent Saunders (former CEO, Allergan), Patrick Hsu (Bioengineering Professor, UC Berkeley), Hugo Barra (CEO, Detect), Austen Allred (CEO, Bloom Institute of Technology), Packy McCormick (Founder, Not Boring), Shrug Capital, Alexandra Botez (influencer), Anthony Pompliano, and many others.
Founded by Kian Sadeghi and also led by Lasse Folkersen, Ph.D., Chief Scientific Officer, and Caio Hachem, Chief Operations Officer, Nucleus Genomics is building a DTC genetic testing platform that provides innovative genetic risk and disposition score analyses on an extensive number of diseases and traits by leveraging whole-genome sequencing (WGS).
The company provides WGS genetic testing kits for users to receive rare variant analysis and polygenic scores across a wide variety of diseases and traits — ranging from breast cancer risk to longevity disposition. Individuals who have done DTC microarray genetic testing from companies such as 23andMe can upload their genotyped DNA on the Nucleus platform to receive a subset of the possible genetic analyses, centering around polygenic scores. These scores are calculated by combining the effects of hundreds, thousands, or even millions of DNA letters that vary from one individual to another.
The additional funding, along with the company’s initial seed financing raised in 2021, will help Nucleus bolster its scientific and engineering team. They are continuing to set up the computational and physical infrastructure required to analyze whole-genome sequencing (WGS) data at scale, customize disease and trait reports, and send genetic testing kits to users.
FinSMEs
15/07/2022